BRPI0411343A - derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos - Google Patents

derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos

Info

Publication number
BRPI0411343A
BRPI0411343A BRPI0411343-8A BRPI0411343A BRPI0411343A BR PI0411343 A BRPI0411343 A BR PI0411343A BR PI0411343 A BRPI0411343 A BR PI0411343A BR PI0411343 A BRPI0411343 A BR PI0411343A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
compositions including
preparation process
medicines
intermediates
Prior art date
Application number
BRPI0411343-8A
Other languages
English (en)
Inventor
Jean-Christophe Carry
Gilles Doerflinger
Arielle Genevois-Borella
Michel Evers
Alain Le Brun
Jean-Paul Martin-Cocher
Pascal Desmazeau
Serge Mignani
Heinz-Werner Kleemann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0411343A publication Critical patent/BRPI0411343A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE 3-(GUANIDINO CARBONIL) HETEROCICLO, PROCESSO DE PREPARAçãO E INTERMEDIáRIOS DESTE PROCESSO, SEU USO COMO MEDICAMENTOS, E COMPOSIçõES FARMACêUTICAS INCLUINDO OS MESMOS". A presente invenção refere-se aos novos compostos da fórmula (I) e seus sais farmaceuticamente aceitáveis. Os compostos inventivos são apropriados, por exemplo, como medicamentos anti-arritmicos com um componente cardioprotetor para profilaxia de infartação e tratamento de infartação e para o tratamento de angina pectoris. Eles também inibem em uma maneira preventiva os processos patofisiológicos associados com o desenvolvimento de dano induzido por isquemia, em particular no disparo de arritmias cardíacas induzidas por isquemia e de insuficiência cardíaca.
BRPI0411343-8A 2003-06-12 2004-05-28 derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos BRPI0411343A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307080A FR2856062B1 (fr) 2003-06-12 2003-06-12 Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/EP2004/005764 WO2004111048A1 (en) 2003-06-12 2004-05-28 3-(guanidinocarbonyl)heterocycle derivatives, preparation process and intermediates of this process, their use as medicaments, and pharmaceutical compositions including them

Publications (1)

Publication Number Publication Date
BRPI0411343A true BRPI0411343A (pt) 2006-07-11

Family

ID=33484382

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411343-8A BRPI0411343A (pt) 2003-06-12 2004-05-28 derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos

Country Status (20)

Country Link
EP (1) EP1641791B1 (pt)
JP (1) JP2006527220A (pt)
AR (1) AR044661A1 (pt)
AT (1) ATE437877T1 (pt)
AU (1) AU2004247350B2 (pt)
BR (1) BRPI0411343A (pt)
CA (1) CA2528382A1 (pt)
CL (1) CL2004001458A1 (pt)
DE (1) DE602004022299D1 (pt)
DK (1) DK1641791T3 (pt)
ES (1) ES2330524T3 (pt)
FR (1) FR2856062B1 (pt)
IL (1) IL172435A0 (pt)
MX (1) MXPA05012970A (pt)
MY (1) MY138896A (pt)
PE (1) PE20050228A1 (pt)
PT (1) PT1641791E (pt)
TW (1) TW200524926A (pt)
UY (1) UY28358A1 (pt)
WO (1) WO2004111048A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007131400A (ru) * 2005-03-01 2009-04-10 Вайет (Us) Соединения циннолина и их применение в качестве модуляторов х-рецепторов печени
CA2661436A1 (en) * 2006-08-24 2008-02-28 Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives
JP2011148751A (ja) * 2010-01-25 2011-08-04 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
CN102603740B (zh) * 2012-03-01 2014-05-14 南京药石药物研发有限公司 4-硝基-7-氮杂吲哚的合成方法
CN105218546B (zh) * 2015-11-04 2017-05-17 上海泰坦科技股份有限公司 1h‑吡咯并[2,3‑b]吡啶‑3‑羧酸甲酯的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121391A1 (en) * 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
JP3162572B2 (ja) * 1993-04-28 2001-05-08 住友製薬株式会社 インドロイルグアニジン誘導体
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
JPH08208602A (ja) * 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd インドロイルグアニジン誘導体
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
JPH09278767A (ja) * 1996-02-15 1997-10-28 Fujisawa Pharmaceut Co Ltd 新規グアニジン誘導体
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
WO1998039300A1 (en) * 1997-03-06 1998-09-11 Toa Eiyo Ltd. CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME

Also Published As

Publication number Publication date
TW200524926A (en) 2005-08-01
JP2006527220A (ja) 2006-11-30
ATE437877T1 (de) 2009-08-15
CL2004001458A1 (es) 2005-05-20
MY138896A (en) 2009-08-28
ES2330524T3 (es) 2009-12-11
AR044661A1 (es) 2005-09-21
DE602004022299D1 (de) 2009-09-10
DK1641791T3 (da) 2009-11-16
AU2004247350A1 (en) 2004-12-23
CA2528382A1 (en) 2004-12-23
EP1641791A1 (en) 2006-04-05
MXPA05012970A (es) 2006-05-25
PE20050228A1 (es) 2005-05-17
IL172435A0 (en) 2006-04-10
UY28358A1 (es) 2004-12-31
FR2856062B1 (fr) 2005-11-11
FR2856062A1 (fr) 2004-12-17
PT1641791E (pt) 2009-09-29
EP1641791B1 (en) 2009-07-29
WO2004111048A1 (en) 2004-12-23
AU2004247350B2 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BR0312134A (pt) Benzoilguanidinas derivadas de cicloalquilas fluoradas e seu emprego como medicamento
PT1058683E (pt) Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
BR0311556A (pt) Derivados de n-((3-oxo-2,3-diidro-1h-isoindol-1-il)acetil)guanidina como inibidores de nhe-1 para o tratamento de enfarte e angina pectoris
KR970061865A (ko) 신규 치환된 구아니딘 유도체, 그의 제조방법, 및 그의 약제학적 용도
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BR0307576A (pt) Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos
EA200400664A1 (ru) Фармацевтические композиции, включающие метформин и глибенкламид, применяемые для лечения сахарного диабета типа ii
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
BR0116571A (pt) Compostos heterocìclicos tendo atividade antibacteriana, processo para sua preparação e composições farmacêuticas contendo os mesmos
WO2015130109A1 (ko) 고시폴 및 펜포르민을 유효성분으로 함유하는 암 치료용 약제학적 조성물
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BRPI0514692A (pt) inibidores do receptor sigma
US20120107276A1 (en) Anti-Arenaviral Compounds
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
JOP20240055A1 (ar) عقار أولي من مشتقات بيروليدون كمنشط جلوكوكيناز
BR0016712A (pt) Derivados do ácido n-benzil-indol-3-il-glioxìlico com efeito antitumor
BR0312701A (pt) Derivados de 3-guanidinocarbonil-1-hete-roaril-indol, processo de preparação, seu uso como medicamentos e composições farmacêuticas os compreendendo
BR0312702A (pt) Derivados de 3-guanidinocarbonil-1-heteroaril-pirrol, processo de preparação e intermediários desse processo, seu uso como medicamentos e composições farmacêuticas compreendendo os mesmos
BRPI0411343A (pt) derivados de 3-(guanidino carbonil) heterociclo, processo de preparação e intermediários deste processo, seu uso como medicamentos, e composições farmacêuticas incluindo os mesmos
MY139310A (en) Pentafluorosulfanylbenzoylguanidines, process for their preparation, their use as. medicament or diagnostic aid, and medicament comprising them
EP0728481A2 (de) Verwendun von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2148 DE 06/03/2012.